Vistusertib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameVistusertib
Drug Alias NameVistusertibum维妥舍替维妥色替AZ-2014AZD-2014 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursRichter's Syndrome +[25] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesRomania +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesFrance National Cancer InstituteEuropean Institute Of OncologyAstrazeneca Plc +[5] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of BirminghamNational Cancer Institute +[4] 
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[16] 
Inactive IndicationsRichter's SyndromeProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A